نتائج البحث - "Elisa Cerqui"

المساهمون: Borlenghi, E, Pagani, C, Zappasodi, P, Bernardi, M, Basilico, C, Cairoli, R, Fracchiolla, N, Todisco, E, Turrini, M, Cattaneo, C, Da Via, M, Ciceri, F, Passamonti, F, Mancini, V, Sciume, M, Cerqui, E, Rossi, G

المصدر: Journal of Geriatric Oncology. 12:550-556

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b4c693278747420098efb3e6a798c11
https://doi.org/10.1016/j.jgo.2020.10.004

View record from ScienceDirect

Full Text via ClinicalKey

7

Postremission therapy with repeated courses of high‐dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long‐term outcome in European leukemia net favorable and intermediate‐risk acute myeloid leukemia

المؤلفون: Doriana Gramegna, Chiara Pagani, Angela Passi, Erika Borlenghi, Chiara Cattaneo, Claudia Crippa, Francesca Schieppati, Margherita Oberti, Daniela Bellotti, Margherita Sciumé, Elisa Cerqui, Cecilia Carbone, Daniela Dalceggio, Giuseppe Rossi, Diego Bertoli, Mirko Farina, Alessandra Tucci, Silvana Archetti, Giulia Soverini

المصدر: Hematological Oncology. 38:754-762

مصطلحات موضوعية: Myeloid, Male, Oncology, Cancer Research, medicine.medical_treatment, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Leukemia, Cytarabine, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Induction Chemotherapy, Hematology, General Medicine, Middle Aged, Prognosis, Combined Modality Therapy, Leukemia, Myeloid, Acute, Treatment Outcome, 030220 oncology & carcinogenesis, Toxicity, outcome, Female, Stem cell, Autologous, medicine.drug, acute myeloid leukemia, consolidation, high dose cytarabine (HDAC), Adult, Aged, Daunorubicin, Humans, Survival Analysis, Transplantation, Autologous, Young Adult, medicine.medical_specialty, Acute, 03 medical and health sciences, Refractory, Internal medicine, Idarubicin, Transplantation, Chemotherapy, business.industry, medicine.disease, business, 030215 immunology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54d77c6f6d4220f03991c44aa55e266b
https://doi.org/10.1002/hon.2806

View record at Wiley

8

Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol

المصدر: Leukemia & Lymphoma. 60:3482-3492

مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Cyclophosphamide, Lymphoblastic Leukemia, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Refractory, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Clofarabine, Philadelphia Chromosome, Prospective Studies, Salvage Therapy, Philadelphia negative, business.industry, Remission Induction, Late stage, Hematology, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Survival Rate, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Adult Acute Lymphoblastic Leukemia, Female, Neoplasm Recurrence, Local, business, Follow-Up Studies, 030215 immunology, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bf4b4890eaad229473e9343bcea9162
https://doi.org/10.1080/10428194.2019.1639170

PDF full text from Publisher

9

The e13a2 BCR‐ABL transcript negatively affects sustained deep molecular response and the achievement of treatment‐free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors

المؤلفون: Elisa Cerqui, Alessandra Tucci, Maria A. Capucci, Giuseppina Ruggeri, Samantha Ferrari, Chiara Pagani, Erika Borlenghi, Francesca Schieppati, Chiara Bottelli, Giuseppe Rossi, Doriana Gramegna, Mirko Farina, Angela Passi, Mariella D'Adda, Adriana Maifredi

المصدر: Cancer. 125:1674-1682

مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, medicine.drug_class, Fusion Proteins, bcr-abl, Real-Time Polymerase Chain Reaction, Disease-Free Survival, Drug Administration Schedule, Tyrosine-kinase inhibitor, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, In patient, Molecular Targeted Therapy, 030212 general & internal medicine, Protein Kinase Inhibitors, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Academic Medical Centers, Dose-Response Relationship, Drug, business.industry, Myeloid leukemia, Middle Aged, Prognosis, medicine.disease, Survival Analysis, respiratory tract diseases, Discontinuation, Gene Expression Regulation, Neoplastic, 030220 oncology & carcinogenesis, Molecular Response, Multivariate Analysis, Imatinib Mesylate, Female, business, Tyrosine kinase, Chronic myelogenous leukemia

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0a61fe2050a9f91cecb25da04d99607
https://doi.org/10.1002/cncr.31977

View record at Wiley

10

Author response for 'Post‐remission Therapy with Repeated Courses of High Dose Cytarabine, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long‐Term Outcome in ELN Favorable and Intermediate‐Risk AML'

المؤلفون: Cecilia Carbone, Chiara Cattaneo, Daniela Bellotti, Elisa Cerqui, Chiara Pagani, Mirko Farina, Erika Borlenghi, Giuseppe Rossi, Francesca Schieppati, Daniela Dalceggio, Giulia Soverini, Angela Passi, Alessandra Tucci, Silvana Archetti, Diego Bertoli, Margherita Oberti, Margherita Sciumé, Doriana Gramegna, Claudia Crippa

مصطلحات موضوعية: Oncology, medicine.medical_specialty, High dose cytarabine, business.industry, Internal medicine, medicine, Idarubicin, Stem cell, Intermediate risk, business, Outcome (game theory), Term (time), medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::498d121e14e81986337c17d4dd43cfd4
https://doi.org/10.1002/hon.2806/v2/response1

تنقيح النتائج